PMID- 20357826
OWN - NLM
STAT- MEDLINE
DCOM- 20100603
LR  - 20211203
IS  - 1476-5551 (Electronic)
IS  - 0887-6924 (Linking)
VI  - 24
IP  - 5
DP  - 2010 May
TI  - EVI1 overexpression in distinct subtypes of pediatric acute myeloid leukemia.
PG  - 942-9
LID - 10.1038/leu.2010.47 [doi]
AB  - Overexpression of the ecotropic virus integration-1 (EVI1) gene (EVI1+), 
      localized at chromosome 3q26, is associated with adverse outcome in adult acute 
      myeloid leukemia (AML). In pediatric AML, 3q26 abnormalities are rare, and the 
      role of EVI1 is unknown. We studied 228 pediatric AML samples for EVI1+ using 
      gene expression profiling and RQ-PCR. EVI1+ was found in 20/213 (9%) of children 
      with de novo AML, and in 4/8 with secondary AML. It was predominantly found in 
      MLL-rearranged AML (13/47), monosomy 7 (2/3), or FAB M6/7 (6/10), and mutually 
      exclusive with core-binding factor AML, t(15;17), and NPM1 mutations. Fluorescent 
      in situ hybridization (FISH) was performed to detect cryptic 3q26 abnormalities. 
      However, none of the EVI1+ patients harbored structural 3q26 alterations. 
      Although significant differences in 4 years pEFS for EVI1+ and EVI1- pediatric 
      AML were observed (28%+/-11 vs 44%+/-4, P=0.04), multivariate analysis did not 
      identify EVI1+ as an independent prognostic factor. We conclude that EVI1+ can be 
      found in approximately 10% of pediatric AML. Although EVI1+ was not an 
      independent prognostic factor, it was predominantly found in subtypes of 
      pediatric AML that are related with an intermediate to unfavorable prognosis. 
      Further research should explain the role of EVI1+ in disease biology in these 
      cases. Remarkably, no 3q26 abnormalities were identified in EVI1+ pediatric AML.
FAU - Balgobind, B V
AU  - Balgobind BV
AD  - Department of Pediatric Oncology/Hematology, Erasmus MC--Sophia Children's 
      Hospital, Rotterdam, The Netherlands.
FAU - Lugthart, S
AU  - Lugthart S
FAU - Hollink, I H
AU  - Hollink IH
FAU - Arentsen-Peters, S T J C M
AU  - Arentsen-Peters ST
FAU - van Wering, E R
AU  - van Wering ER
FAU - de Graaf, S S N
AU  - de Graaf SS
FAU - Reinhardt, D
AU  - Reinhardt D
FAU - Creutzig, U
AU  - Creutzig U
FAU - Kaspers, G J L
AU  - Kaspers GJ
FAU - de Bont, E S J M
AU  - de Bont ES
FAU - Stary, J
AU  - Stary J
FAU - Trka, J
AU  - Trka J
FAU - Zimmermann, M
AU  - Zimmermann M
FAU - Beverloo, H B
AU  - Beverloo HB
FAU - Pieters, R
AU  - Pieters R
FAU - Delwel, R
AU  - Delwel R
FAU - Zwaan, C M
AU  - Zwaan CM
FAU - van den Heuvel-Eibrink, M M
AU  - van den Heuvel-Eibrink MM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20100401
PL  - England
TA  - Leukemia
JT  - Leukemia
JID - 8704895
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (MDS1 and EVI1 Complex Locus Protein)
RN  - 0 (MECOM protein, human)
RN  - 0 (NPM1 protein, human)
RN  - 0 (RNA, Messenger)
RN  - 0 (Transcription Factors)
RN  - 117896-08-9 (Nucleophosmin)
SB  - IM
MH  - Biomarkers, Tumor/*genetics
MH  - Child
MH  - Child, Preschool
MH  - Chromosome Aberrations
MH  - Chromosomes, Human, Pair 3/*genetics
MH  - DNA-Binding Proteins/*genetics
MH  - Female
MH  - Gene Expression Profiling
MH  - *Gene Expression Regulation, Leukemic
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Leukemia, Myeloid, Acute/*genetics/metabolism
MH  - MDS1 and EVI1 Complex Locus Protein
MH  - Male
MH  - Nucleophosmin
MH  - Oligonucleotide Array Sequence Analysis
MH  - Prognosis
MH  - Proto-Oncogenes/*genetics
MH  - RNA, Messenger/genetics/metabolism
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Survival Rate
MH  - Transcription Factors/*genetics
EDAT- 2010/04/02 06:00
MHDA- 2010/06/04 06:00
CRDT- 2010/04/02 06:00
PHST- 2010/04/02 06:00 [entrez]
PHST- 2010/04/02 06:00 [pubmed]
PHST- 2010/06/04 06:00 [medline]
AID - leu201047 [pii]
AID - 10.1038/leu.2010.47 [doi]
PST - ppublish
SO  - Leukemia. 2010 May;24(5):942-9. doi: 10.1038/leu.2010.47. Epub 2010 Apr 1.